Progyny (NASDAQ:PGNY) EVP Allison Swartz Sells 599 Shares

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 599 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $25.08, for a total value of $15,022.92. Following the completion of the transaction, the executive vice president owned 82,378 shares of the company’s stock, valued at approximately $2,066,040.24. This represents a 0.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Allison Swartz also recently made the following trade(s):

• On Wednesday, June 3rd, Allison Swartz sold 1,199 shares of Progyny stock. The stock was sold at an average price of $25.02, for a total value of $29,998.98.

Progyny Stock Up 1.5%

Shares of NASDAQ PGNY opened at $25.86 on Friday. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $28.75. The business has a 50-day simple moving average of $20.58 and a two-hundred day simple moving average of $22.30. The company has a market cap of $2.03 billion, a P/E ratio of 33.58, a P/E/G ratio of 2.25 and a beta of 1.03.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. During the same quarter last year, the company earned $0.17 EPS. The firm’s revenue was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities research analysts anticipate that Progyny, Inc. will post 1.07 EPS for the current year.

Progyny announced that its Board of Directors has initiated a share buyback plan on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to reacquire up to 10.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Institutional Trading of Progyny

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after buying an additional 235,513 shares during the last quarter. State Street Corp lifted its position in Progyny by 1.5% in the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its position in Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after purchasing an additional 859,289 shares during the last quarter. Wellington Management Group LLP lifted its position in Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. BTIG Research dropped their price target on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Canaccord Genuity Group upgraded Progyny from a “hold” rating to a “buy” rating and lifted their price target for the company from $19.00 to $30.00 in a research report on Tuesday, May 19th. Bank of America lifted their price target on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, Citizens Jmp lifted their price target on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.